Pancreatic Cancer Research

ResearcherNanjing Drum Tower HospitalActive in the last 2 years

Huizi Sha

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6820-8885; OpenAlex author ID A5103950900. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer. Co-author DOI 10.3389/fonc.2026.1745466↗
  2. Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgica… Co-author DOI 10.1080/07853890.2025.2541314↗
  3. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: … Co-author DOI 10.1038/s41392-024-01857-6↗
  4. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, pha… Co-author DOI 10.3389/fimmu.2024.1210859↗
  5. [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. Co-author DOI 10.3760/cma.j.cn112152-20231223-00383↗
  6. Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report. Co-author DOI 10.3389/fimmu.2023.1277810↗
  7. Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancre… Co-author DOI 10.3389/fonc.2022.1015232↗
  8. AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study. Co-author DOI 10.3389/fonc.2021.693386↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Du · 5 shared papers, 2021–2025 · strength 0.88
  2. Baorui Liu · 5 shared papers, 2021–2024 · strength 0.84
  3. Fan Tong · 4 shared papers, 2023–2026 · strength 0.81
  4. Xin Qiu · 3 shared papers, 2021–2024 · strength 0.50
  5. Qiao-Li Wang · 2 shared papers, 2024 · strength 0.36
  6. Yudong Qiu · 2 shared papers, 2022–2025 · strength 0.35
  7. Changchang Lu · 2 shared papers, 2021–2024 · strength 0.35
  8. Jingjing Chen · 1 shared paper, 2026 · strength 0.26
  9. Juan Du · 1 shared paper, 2026 · strength 0.26
  10. Lu Zou · 1 shared paper, 2026 · strength 0.26
  11. Song Zhang · 1 shared paper, 2025 · strength 0.21
  12. Jun Chen · 1 shared paper, 2025 · strength 0.21
  13. Elyar Abaydulla · 1 shared paper, 2025 · strength 0.21
  14. Shanshan Shen · 1 shared paper, 2025 · strength 0.21
  15. Hao Cheng · 1 shared paper, 2025 · strength 0.21
  16. Liang Qi · 1 shared paper, 2023 · strength 0.17
  17. Juan Du · 1 shared paper, 2023 · strength 0.17
  18. Juan Du · 1 shared paper, 2024 · strength 0.15
  19. Hua Jiang · 1 shared paper, 2024 · strength 0.15
  20. Jun Wu · 1 shared paper, 2024 · strength 0.15
  21. B R Liu · 1 shared paper, 2024 · strength 0.15
  22. Wangshu Dai · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.